ASPN

ASPN is a boom-bust story that just went bust. FY2025 revenue fell 40.1% to $271M after a $453M peak in 2024, driven by PyroThin thermal-barrier sales collapsing from $306.8M to $168.9M — sold 'primarily to GM.' The MD&A and Risk Factors make the fragility explicit: revenue rides on 'a limited number of direct customers,' contracts carry 'no minimum commitments,' and results hinge on OEM 'market share and production declines' plus EV cell-chemistry and pack-architecture choices ASPN does not control. The five-year revenue path ($122M→180M→239M→453M→271M) shows how violently this whipsaws, which management itself flags: 'Our revenue may fluctuate, which may result in a high degree of variability in our results of operations.'

The headline -$390M net loss (from +$13.4M) is largely non-cash — operating cash flow stayed positive at $32.9M and gross profit was still $46.0M — so this is an impairment-driven writedown of capacity built for EV volumes that didn't arrive, not an imminent solvency event. Retained earnings sank to -$1.05B and equity fell 61.7% to $236M. But even stripping the impairment, the underlying picture is weak: 17.0% gross margin, $13.4M R&D, and revenue still shrinking leave little operating profit, and capex of $37.4M exceeds operating cash flow.